In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Amazon Versus Biotech: How The IPO Class Of '97 Worked Out

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

Financing Growth Risk Management
Advertisement

Latest From Market Intelligence

Deals In Depth: August 2017

Dermira aims to develop Roche's discontinued asthma antibody lebrikizumab in atopic dermatitis, in a deal worth $1.4 billion; Gilead entered CAR-T race with $11.9 billion buy of Kite Pharma. Biopharma funding was way up thanks to a $1.1 billion fundraise by Roivant Sciences.

Deals Market Intelligence

In Vivo's Deals Of The Month, September 2017

In Vivo's editors pick September's most significant deals, including lucrative partnerships for Halozyme and the pursuit of Dimension Therapeutics. (Free article.)

BioPharmaceutical Deals

CRISPR/Cas9 Patent Battle: What's Happened, What's Next?

With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.

Regenerative Medicine Intellectual Property

In Vivo's Deals Of The Century: A Timeline

When it comes to deal-making, In Vivo's editors have always been quick to single out transactions that we feel will spark trends or otherwise have a major impact on the life sciences industry. Below, an expandable timeline of the deals we chose as bellwethers for pharma and medtech in each year of this still-young century and what we said about them at the time. (Free article.)

BioPharmaceutical Medical Device

Deals In Depth: July 2017

AstraZeneca and Merck signed a broad targeted therapy and immuno-oncology alliance worth $8.5 billion; Japanese pharma Mitsubishi Tanabe boosted its neuroscience assets with the acquisition of NeuroDerm. Biopharma financing decreased from June, while device funding went up.

Deals Market Intelligence

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device
See All
UsernamePublicRestriction

Register